sponsored
PatientsVille.com Logo

PatientsVille

Seroquel Medical Research Studies

Up-to-date List of Seroquel Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Seroquel Medical Research Studies

Rank Status Study
1 Not yet recruiting Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine
Conditions: Dementia;   Delirium
Interventions: Drug: Quetiapine 25 mg gel applied topically;   Drug: Quetiapine 25 mg tablet by mouth;   Drug: Quetiapine 25 mg rectal suppository
Outcome Measures: Serum quetiapine levels after topical application (Visit 1);   Serum quetiapine levels after oral administration (Visit 2);   Serum quetiapine levels after rectal administration (Visit 3)
2 Unknown  A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder
Condition: Bipolar Disorder
Intervention: Drug: quetiapine fumarate tablet (Seroquel)
Outcome Measures: The primary efficacy variable for this study is the YMRS total score change from baseline to Day 28 (LOCF).;   To evaluate the effectiveness of quetiapine fumarate;   To evaluate the relationship between the serum brain-derived neurotrophic factor and quetiapine fumarate;   To evaluate the safety and tolerability of quetiapine fumarate
3 Unknown  Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
Conditions: Abnormal Mental State;   Schizophrenia
Intervention: Drug: Quetiapine(Seroquel-XR) 50~800mg a day
Outcome Measures: California Verbal Learning Test;   verbal & spatial 2-back test, Digit Span, 3-7 CPT, WCST, Rey-CFT, TMT A & B, COWAT, SOPS, PANSS, SAS, PAS, AIHQ, BIS
4 Unknown  Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania
Conditions: Bipolar, Mania;   Utapine;   Seroquel
Interventions: Drug: Utapine;   Drug: Seroquel
Outcome Measure:
5 Recruiting The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope
Condition: Major Depressive Disorder
Interventions: Drug: SSRI monotherapy;   Drug: Seroquel XR adjunctive
Outcome Measures: Change from baseline in HDRS scale;   Change from baseline in CGI, BDI, and YMRS scales
6 Unknown  Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia
Condition: Acute Schizophrenia
Interventions: Drug: Quetiapine fumarate;   Drug: Haloperidol
Outcome Measures: The primary objective of this study is to evaluate the efficacy of quetiapine fumarate in improving agitation and aggression symptoms for the schizophrenic patients;   The response rate of quetiapine in improving agitation and aggression symptoms - the efficacy of quetiapine - the safety and tolerability of quetiapine - differences between quetiapine and haloperidol
7 Unknown  Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
Conditions: Schizophrenia;   Psychosis
Intervention: Drug: Quetiapine XR
Outcome Measures: The primary efficacy variable is the change in aggression between admission and day 8 of treatment with Quetiapine XR as measured by the OAS.;   Measuring psychotic symptomatology change from baseline in BPRS-Total Score in aggressive, psychotic patients managed with Quetiapine XR;   Measuring the incidence of adverse events (including Extrapyramidal symptoms) by the change from baseline in SAS and BAS and subjective reports;   Measuring the incidence of concomitant benzodiazepine and other permitted medication use
8 Unknown  Trial of Quetiapine in Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention: Drug: Quetiapine
Outcome Measures: Primarily we will seek to show that Quetiapine is superior to placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorders Inventory-2.;   We seek to show that Quetiapine is superior to placebo in reducing anxiety, depression, obsessionality, or weight gain in patients with AN. We also will seek to show that Quetiapine is superior to placebo at reducing positive and negative symptoms.
9 Recruiting Quetiapine Pharmacotherapy for Cannabis Dependence
Condition: Cannabis Dependence
Interventions: Drug: Quetiapine;   Drug: Placebo
Outcome Measures: Marijuana Use;   Marijuana Abstinence;   Urine toxicology;   Marijuana withdrawal symptoms;   Marijuana craving;   Sleep disturbance
10 Unknown  Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR
Condition: BIPOLAR DISORDER
Intervention: Drug: quetiapine
Outcome Measures: Efficacy of quetiapine as a treatment for acute mania and depression, and of as a manutence treatment.;   Assess the pharmacodynamics of quetiapine by neurotrophins in blood samples.
11 Recruiting Gao Bipolar Spectrum Lithium/Quetiapine Study
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Quetiapine
Outcome Measures: Time to study discontinuation;   Lithium vs. Quetiapine effects on general cardiovascular disease risk and role effects on general cardiovascular disease risk and role impairment
12 Not yet recruiting Safety and Tolerability of Quetiapine in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Extended-release quetiapine fumarate
Outcome Measures: Dose-limiting toxicity;   Adverse events
13 Recruiting Post-Traumatic Stress Disorder (PTSD) and Seroquel
Condition: Post-Traumatic Stress Disorder
Intervention: Drug: Seroquel
Outcome Measures: The primary outcome will be the change from baseline in PTSD symptomatology at the week 8 timepoint.;   The secondary outcome will be the change from baseline in PTSD symptomatology at the Week 8 timepoint.
14 Recruiting European Drug Utilization Study
Condition: Major Depressive Disorder (MDD)
Intervention:
Outcome Measures: Patient age (mean and range);   Patient gender (%);   Diagnosis for which Seroquel XR was prescribed (% of Major Depressive Disorder- MDD);   Patients hospitalized for any psychiatric condition (n, %);   Daily dose of Seroquel XR (mode and range);   Patient referral pathway (%);   Participating psychiatrist practice setting (%);   Percent of patients experiencing psychotic symptoms at initiation of Seroquel XR (n, %)
15 Unknown  Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Quetiapine Fumarate Extended Release;   Other: healthy control
Outcome Measures: change from baseline Pittsburgh Quality Index total scores at 4 weeks;   change from baseline Pittsburgh Quality Index total scores at 2 weeks;   change from baseline Pittsburgh Quality Index total scores at 4 days;   change from baseline in sleep architecture measured using polysomnography at 4 weeks;   number of participants with adverse events
16 Recruiting Efficacy of Quetiapine for Pediatric Delirium
Condition: Delirium
Interventions: Drug: quetiapine;   Other: Placebo
Outcome Measures: Time to first resolution of delirium;   Total ICU days with delirium
17 Unknown  Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
Conditions: Schizophrenia;   Bipolar
Intervention: Drug: Aripiprazole; Quetiapine
Outcome Measure:
18 Recruiting Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium
Condition: Delirium
Interventions: Drug: Quetiapine;   Drug: Haloperidol;   Drug: Placebo
Outcome Measures: Time to first resolution of delirium;   Days in delirium during the study;   Duration of delirium;   Severity of delirium (highest Nu-DESC score, mean episode Nu-DESC score);   ICU and hospital mortality;   ICU and hospital length of stay;   Length of mechanical ventilation;   Time spent deeply sedated (RASS <3);   Episodes of subject-initiated device removal;   Use of haloperidol therapy (including total dose in haloperidol equivalents during the study, number of doses, number of days of therapy, use of rescue IV haloperidol);   Average daily and maximum total antipsychotic drug dose in haloperidol equivalents;   Duration of study drug administration;   Use of benzodiazepines;   Use of opioids;   QTc prolongation;   Extrapyramidal symptoms;   Neuroleptic malignant syndrome
19 Recruiting Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Valproate;   Drug: Oxcarbazepine;   Drug: Quetiapine;   Drug: Olanzapine;   Drug: Ziprasidone
Outcome Measures: Change from baseline in Young Mania Rating Scale at 2 weeks and 6 weeks;   rate of dropout (treatment discontinuation);   Clinical Global Impressions (CGI) Scale;   Brief Psychiatric Rating Scale;   Global Assessment Scale;   Treatment Emergent Symptom Scale;   Hamilton Anxiety Rating Scale;   Hamilton Depression Rating Scale
20 Unknown  Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Insomnia
Intervention: Drug: quetiapine
Outcome Measures: The primary objective is to determine whether quetiapine can increase total sleep time and reduce time awake in patients with AD and sleep disturbance.;   Dose-response relationship of quetiapine and sleep in AD patients?;   Are there sleep architecture changes from quetiapine?;   Do the primary sleep variables change relative to placebo at any weekly time or dose point?;   Are caregivers, blind to treatment status, able to detect changes in sleep quality in the patients for quetiapine relative to placebo?;   Does quetiapine used at single bedtime dosing for potential nighttime soporific effect have a measurable impact on neuropsychiatric symptoms other than insomnia?

These studies may lead to new treatments and are adding insight into Seroquel etiology and treatment.

A major focus of Seroquel research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Seroquel